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Abstract: miRNAs are a class of over 5000 noncoding RNAs that regulate more than half of the
protein-encoding genes by provoking their degradation or preventing their translation. miRNAs are
key regulators of complex biological processes underlying several cardiovascular disorders, including
left ventricular hypertrophy, ischemic heart disease, heart failure, hypertension and arrhythmias.
Moreover, circulating miRNAs herald promise as biomarkers in acute myocardial infarction and
heart failure. In this context, this review gives an overview of studies that suggest that miRNAs
could also play a role in valvular heart diseases. This area of research is still at its infancy, and further
investigations in large patient cohorts and cellular or animal models are needed to provide strong
data. Most studies focused on aortic stenosis, one of the most common valvular diseases in developed
countries. Profiling and functional analyses indicate that miRNAs could contribute to activation of
aortic valve interstitial cells to a myofibroblast phenotype, leading to valvular fibrosis and calcification,
and to pressure overload-induced myocardial remodeling and hypertrophy. Data also indicate that
specific miRNA signatures, in combination with clinical and functional imaging parameters, could
represent useful biomarkers of disease progression or recovery after aortic valve replacement.
Keywords: microRNAs; valvular heart diseases; biomarkers; cellular and animal models
1. Introduction
Valvular heart disease (VHD) is a major leading cause of cardiovascular mortality. According to
the most recent statistics, the prevalence of any VHD in the entire U.S. population is 2.7%, with
0.4% aortic stenosis, 0.5% aortic regurgitation, 0.1% mitral stenosis, and 1.7% mitral regurgitation [1].
Prevalence of VHD increases with age, reaching about 13% in patients ě75 years old [2].
2. Valvular Heart Disease Pathophysiology
2.1. Aortic Stenosis
The prevalence of moderate or severe aortic stenosis (AS) in patients ě75 years equals 2.8% [2].
No medical therapy currently exists for AS, and approximately 50% of patients with severe AS are
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admitted for cardiothoracic surgery, and about 40% undergo aortic valve replacement. Calcific aortic
stenosis (AS) is one of the most common VHD in developed countries. In addition to older age,
congenital anomalies of the aortic valve (bicuspid valve) are major risk factors for calcific AS.
The pathophysiological mechanisms of calcific AS are complex and remain poorly understood.
Lipoprotein deposition, chronic inflammation, osteoblastic transition of valve interstitial cells and
active leaflet calcifications are likely to be involved.
A hallmark of disease progression is a misalignment of collagen fibres within the fibrosa layer,
proximal to the aorta that produces thickened, fibrotic leaflets, and overall stiffened leaflet with
altered biomechanical functionality. Later accumulation of calcific nodules worsens the phenomenon.
Alterations of leaflet dynamics during cardiac cycle results in modified shear stresses, leading to
phenotypic changes of leaflet lining valve endothelial cells (VEC), and infiltration of inflammatory
cells in the valve tissue. In addition, VEC can undergo mechanical strain and Wnt/β-catenin
signaling-dependent endothelial-to-mesenchymal transition, invade the leaflet interstitium, and play
an active role in valve remodelling. These phenotypic changes mainly occur on the fibrosa side of
the valve leaflets, subjected to more disturbed flow than the ventricular side. Differentiation of
valve interstitial cells (VIC) in myofibroblasts (expressing smooth muscle cell protein markers)
would be responsible for fibrotic accumulation of collagen during the initial stages of calcific AS.
Osteoblastic differentiation of VIC would lead to the formation of the osteogenic nodules in valve
leaflets. Whether the fibrotic and calcific processes are interrelated is uncertain. Mechanistically,
active transforming growth factor (TGF)-β1 controls the expression of proteins associated with VIC
myofibroblast transition [3]. In vitro incubation of VICs with TGF-β1 induces the expression of
aortic smooth muscle actin and production of type I collagen. TGF-β1 also causes the formation of
apoptosis-driven dystrophic calcific nodules that occurs as a response to augmented contractility and
intercellular tension. Activation of the Wnt/β-catenin signalling pathway promotes myofibroblastic
activation through non-canonical TGF-β1-dependent activation of p38 mitogen-activated protein
kinase (MAPK). In addition to TGF-β1, elevated levels of Bone morphogenetic protein 2 (BMP-2)
and BMP-4 expression, two pro-osteogenic cytokines belonging to the TGF-β superfamily, have been
observed in stenotic calcific aortic valve disease (CAVD) leaflets.
Chronic inflammation is a major feature of calcific AS. Inflammatory processes are associated with,
and may be responsible for the alterations in the valve extracellular matrix (ECM) through release of
proteases by inflammatory cells. Infiltrating macrophages may also actively contribute the deposition
of calcium phosphate minerals.
Recently, it has been proposed that lipid accumulation in the valve leaflet would promote
the inflammatory response and lesion development in early calcific AS, leading to fibrocalcific
remodelling. Lipoprotein(a), composed of a low density lipoprotein (LDL)-like particle in which
apolipoprotein(a) is covalently bound to apolipoprotein B, and VIC-derived autotaxin, a
member of the ectophosphodiesterase/nucleotide phosphohydrolase (ENPP) family converting
lysophosphatidylcholine to lysophosphatidic acid, may induce valve calcification by regulating
inflammation-induced bone morphogenetic protein (BMP) [4]. Expression of NPP1 and 5’-nucleotidase
by VICs could mediate mineralization of the aortic valve through the adenosine A2 receptor [5].
Furthermore, shear stress encountered in stenotic aortic valve activates platelets, generating platelet
microparticles, and cause profound hemostasis disorders mainly due to the loss of high molecular
weight von Willebrand factor multimers [6,7]. Tissue factor, the key initiator of coagulation expressed
within the valve itself, is likely to be involved in fibrin deposition, infiltration of lipid and macrophages.
Thus, prothrombotic and inflammatory mechanisms likely promote the progression of disease.
In addition to the valve alterations, the AS-associated chronic hemodynamic stress causes left
ventricle remodelling due to cardiomyocyte hypertrophy and increased production of ECM proteins in
the myocardium. The resulting contractile alteration can evolve to overt heart failure. TGF-β is a key
player in pathological remodeling of the heart that occurs in response to pressure overload through
the induction of interstitial fibrosis and cardiomyocyte hypertrophic growth [8].
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In AS, aortic valve replacement (AVR), either surgical or via transcatheter implantation, is the only
treatment that improves survival [9]. A major management challenge is deciding on the correct timing
of aortic valve replacement. In this context, biomarkers could be very useful for the establishment of
risk stratification in asymptomatic patients and the identification of determinants of poor prognosis
in symptomatic subjects. A key element would be to identify patients with asymptomatic severe AS
who may benefit from early AVR. AVR is indicated in patients with severe AS who develop symptoms
and/or left ventricular (LV) systolic dysfunction (LV ejection fraction < 50%). At earlier stages of
the disease, LV ejection fraction often remains normal even though the alterations in LV myocardial
structure and function can already be irreversible. Such LV remodelling process may occur in patients
with moderate AS, in the absence of clear symptoms, and can trigger biomarkers release (i.e., B-type
natriuretic peptide (BNP)).
2.2. Mitral Valve Disorders
Mitral valve disease is the other most common valvular lesion, and a frequent cause of heart
failure and mortality. Moderate mitral regurgitation occurs at a frequency of 9.3% in patients
aged ě75 years [2]. According to Carpentier’s functional classification [10], the frequency order
is as follows: Type I (congenital mitral regurgitation and endocarditis) < Type IIIa (rheumatic heart
disease, systemic lupus erythematosus, antiphospholipid syndrome) < Type II (myxomatous mitral
regurgitation) < Type IIIb (ischemic mitral regurgitation, LV dysfunction, dilated cardiomyopathy).
Mitral valve is composed of the annulus, anterior and posterior leaflets, and chordae that attach
the leaflets to papillary muscles. The normal mitral leaflets comprise three tissue layers (atrialis,
spongiosa, and fibrosa/ventricularis) and a continuous endothelial surface layer. VICs are located in
the deep sub-endothelial layers. The fibrosa contains collagen fibres that are aligned parallel to the
leaflet free edge. This layer is connected to the mitral annulus and faces the LV.
Structural alterations in the mitral valve and secondary changes due to ventricle remodelling both
contribute to the development of valve insufficiency. Mitral valve insufficiency affects cardiac function
mechanically, because of required elevated filling pressure, but also results in impaired contractility
and electrical instability.
Mitral regurgitation (MR) represents a leakage of blood from the left ventricle backwards into the
left atrium during systole, which may be due to a primary abnormality (often referred to as organic
MR) of one or more components of the valve apparatus or may be secondary (often referred to as
functional MR) to LV dysfunction.
The main causes of primary MR include degenerative mitral valve diseases, such as myxomatous
degeneration leading to eventual mitral valve prolapse, fibroelastic deficiency disease, acute rheumatic
carditis, infective endocarditis, congenital diseases, use of certain drugs, and mitral annulus
calcification. Secondary causes of MR include coronary artery disease (CAD), dilated cardiomyopathy,
and hypertrophic cardiomyopathy.
Mitral valve prolapse can be a feature of myxomatous valve disease, but can also occur in
patients with normal mitral valve leaflets. Besides, prolapse and mitral valve leaflet thickening
can be observed in several inherited connective tissue disorders, including Marfan syndrome, and
Ehlers-Danlos syndrome.
In ischemic mitral regurgitation (IMR), which often affects patients surviving a myocardial
infarction or with dilated cardiomyopathy, leaflet area cannot compensate LV dilatation, and the
leaflets become stiffer and undergo fibrosis. Remodelling or distortion of LV structure leads to
papillary muscle displacement, leaflet tethering, and impaired coaptation, with a substantial risk of
death [11]. In the ischemic setting, it is of paradigm importance to improve the understanding of the
adverse cellular and mechanical processes leading to mitral leaflet insufficiency, and regurgitation.
Ischemic MR reflects maladaptive valve apposition relative to changes in LV geometry.
Using animal models of ischemic MR, investigators have reported that leaflet thickening results
from a dynamic adaptation to increased leaflet stresses. Reactivation of endothelial-to-mesenchymal
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transition has been described with possible roles for TGF-β, BMP, vascular endothelial growth factor,
and Notch signalling.
Upregulation of TGF-β1 has been reported in animals and humans with MVP and is thought to
contribute to extracellular matrix remodeling and fibrosis [12]. A recent mRNA profiling study [13]
indicates that (1) TGF-β signaling is increased in myxomatous mitral valve tissue because of increased
ligand expression and derepression of canonical mothers against decapentaplegic homolog (SMAD)
2/3 signaling; (2) canonical BMP and Wnt/β-catenin signaling pathways are increased in myxomatous
mitral valve degeneration (MMVD); (3) TGF-β, BMP, and Wnt/β-catenin pathways in MMVD are
associated with matrix remodeling, procalcific and proproliferative cellular processes; and (4) activated
immune cells are localized to myxomatous mitral valves, which possibly contribute to maladaptive
wound repair response. Fibrogenic, osteogenic, and proliferative signaling are robustly activated
in myxomatous valve tissue, and derepression of these signaling cascades may be a key permissive
mechanism promoting disease progression. Although some of these changes appear reminiscent
of the molecular signature present in calcific aortic valve disease, it is critical to note that the
phenotypic consequences of these changes are dramatically different and are likely to act in a highly
context-dependent manner.
Thus, mitral valve is a dynamic structure that adapts to continuous mechanical and biological
stresses and is influenced by ventricular pathology. Such valve plasticity depends on several factors,
including signals intrinsic to the valve, paracrine signals from the left ventricular wall, activation of
the endothelium, and possible engraftment of blood-borne cells.
Surgery, mitral valve replacement or repair, is the only therapy available for severe symptomatic
primary MR, especially in organic forms of MR [14].
3. miRNA Expression in Valvular Heart Disease (VHD): Profiling Studies
In both aortic and mitral valve diseases, early detection and modification of the mechanisms of
disease progression could limit valve degeneration and related clinical complications [15]. Over the
time, symptoms can develop or ejection fraction can deteriorate and lead to irreversible LV impairment.
Biomarkers that reflect the degree of severity of valve disease and early LV dysfunction would be highly
valuable. In the last decade, a big focus has been made on natriuretic peptides (BNPs). BNPs, produced
in response to myocardial wall stress, correlate well with disease severity and symptomatic status and
can also be useful for prognosis [16–18]. BNPs have a role in the risk stratification of VHD patients as
well as in routine surveillance and monitoring, and are being incorporated into clinical management
together with functional imaging modalities [19]. However, additional biomarkers are still required to
identify early stages of disease progression in asymptomatic patients, and/or to better define correct
timing of surgery to preserve ventricular function.
MicroRNAs (miRNAs) might fulfill this role. miRNAs are small non coding RNA of about
21-nucleotide (nt)-long that regulate gene expression at the post-transcriptional level [20]. More than
1000 miRNA have been identified in humans, possibly targeting ~30% of human genes [21].
Target mRNAs and biological roles have been assigned to only a few dozen miRNAs although
almost every process investigated seem to be regulated by miRNAs. The expression of many miRNAs
shows tissue- or developmental stage-specific patterns. Most importantly, miRNA signatures have
been associated with a wide panel of human diseases [22]. In the cardiovascular field, circulating
miRNAs are currently investigated as biomarkers in acute myocardial infarction and heart failure [23].
In addition, miRNAs likely represent key actors of biological processes underlying cardiovascular
disorders, such as LV hypertrophy, ischaemic heart disease, heart failure, hypertension and arrhythmias.
In this context, the present review aims at giving an overview on current knowledge of the role of
miRNAs in the most common VHDs.
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3.1. Aortic Stenosis
3.1.1. Aortic Valves
Five studies investigated the expression of miRNAs in aortic valve leaflets from AS patients
undergoing AVR, by using a miRNA candidate approach or miRNA microarray (Table 1).
Microarray data were validated by quantitave real-time polymerase chain reaction (qPCR) unless
indicated. The first study by Nigam et al. [24] analyzed bicuspid aortic valve samples from patients
with AS or aortic insufficiency (AI), indicating a downregulation of miR-26a, miR-30b, and miR-195 in
the aortic valves of patients requiring AVR due to AS, compared to AI. Yanagawa et al. [25] compared
miRNA microarray profiles in bicuspid valves vs. tricuspid valves of AS patients. 35 miRNA were
differentially expressed between bicuspid and tricuspid valves. Downregulation of miR-141 was
confirmed by qPCR. Zhang et al. [26] found a downregulation of miR-30b (qPCR) in calcific tissue of
aortic valves vs. non-calcific adjacent tissue. In the study by Patel et al. [27] Bicuspid aortic valves BAVs
expressed lower levels of miR-148-3p as compared to control aortic valve leaflets. Ohukainen et al. [28]
performed a microarray analysis of calcific stenotic aortic valves and control valves and identified
3 downregulated miRNAs (miR-374b*, miR-602, miR-939) and upregulation of miR-125b.
3.1.2. Left Ventricle
Five other studies aimed at identifying differential miRNA expression in LV biopsies from AS
patients requiring AVR vs. surgical controls or from AS patients with severe or non-severe fibrosis.
Two of them indicate that miR-133a is not only upregulated in myocardium of AS patients, but
also carries predictive value of LV mass normalisation one year after valve replacement [29,30].
Villar et al. [31] found elevated levels of miR-21 in AS patients compared to controls. Patients with
left ventricular hypertrophy due to AS showed reduced levels of miR-1, which was restored after
transcatheter aortic valve implantation [32]. By miRNA microarray analysis, Beaumont et al. [33]
found 99 downregulated miRNAs and 19 up-regulated in endomyocardial biopsies of AS patient with
or without severe fibrosis. qPCR experiments validated the downregulation of miR-122 and miR-18b
in patients with severe fibrosis compared with those with no severe fibrosis and control subjects.
These two miRNAs potentially target TGF-β1.
3.2. Mitral Valve Disease
Very few studies investigated miRNA profiles in mitral valves from mitral valve disease patients,
and the only available studies were designed to assess the influence of atrial fibrillation (AF) more
than the effect of the disease itself as compared to controls. Because a recent review has extensively
addressed the role of miRNAs in AF [34], this particular topic will not be documented here.
3.2.1. Atrium
The expression of 28 miRNAs was differentially altered in the right atrium of patients with
mitral stenosis (MS) and AF as compared to patients with mitral stenosis but no history of AF [35].
Another study showed miRNA dysregulation in MS with AF, with differences between right and left
atrium [36]. Finally, miRNA expression profiles were compared in left and right appendages from
patients with rheumatic mitral valve disease, and sinus rhythm or AF [37].
3.2.2. Mitral Valves
In a study available in the form of an abstract, high-throughput RNA sequencing coupled with
miRNA sequencing was performed to identify novel molecular targets as well as upstream regulators
contributing to MMVD [38]. In this study, 67 miRNAs were differentially expressed between normal
and myxomatous mitral valves. mRNA levels of the genes encoding TGF-β-induced factor homeobox 1,
salt-inducible kinase 1, tissue inhibitor of metalloproteinase 4, and cyclin-dependent kinase inhibitor
1C mRNA levels were decreased in myxomatous tissue, and miRNAs predicted to target these genes
(e.g., miR-656, miR-379-3p, miR-664a-3p, and miR-34c-5p) were significantly increased.
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Table 1. miRNA profiling studies for valvular heart disease (VHD).
Origin Methods Dysregulated miRNAs Study Details
Aortic stenosis
Aortic valve leaflets [24] Microarray qPCR Downregulated: 26a, 30b, 195 9 patients with BAV (AS vs. aorticinsufficiency requiring AVR)
Aortic valve leaflets [26] qPCR Downregulated: 30b 10 AS patients requiring AVR(calcific vs. adjacent tissue)
Aortic valve leaflets [27] qPCR Downregulated: 148a-3p 4 BAVs vs. healthy aortic valves
Aortic valve leaflets [28] Microarray qPCR Upregulated: 125bDownregulated: 374b*, 602, 939 20 calcific AS valves vs. 6 control valves
Aortic valve leaflets [25] Microarray qPCR
Upregulated: 151-3p, 152, 030e, 032, 145, 768-5p, 190, 373*
Downregulated: 141, 370, 022, 1972, 330-5p, 566-pre, 1469,
1908, 648-pre, 637, 1282, 622, 486-3p, 187, 1909*, 564, 027a,
194*, 125b-1-pre, 551a-pre, 575, 585-pre, 211-pre, 449b*,
124-3-pre, 185-pre, 1202
19 BAVs vs. 17 TAVs from
AS patients requiring AVR
LV intraoperative biopsies [29] qPCR Upregulated: 133a 46 AS patients requiring AVR
LV intraoperative biopsies [31] qPCR Upregulated: 21 75 AS patients requiringAVR vs. 32 surgical controls
LV intraoperative biopsies [32] qPCR Downregulated: 1 5 AS patients before TAVI vs. healthy controls
Endomyocardial biopsies [33] Microarray qPCR Downregulated: 18b, 122 28 AS patients with severe myocardialfibrosis vs. non-severe fibrosis
LV intraoperative biopsies [30] qPCR Upregulated: 133a 74 AS patients requiring AVR
Mitral valve disease
Tissues from the right and the
left atrial appendages [37] Microarray qPCR
Upregulated: 4484
Downregulated: 1, 23b-3p, 26a-5p, 30c-5p, 125b-5p, 133b,
143-3p, 145-5p, 4454
18 rheumatic mitral valve disease patients
(10 AF vs. 8 SR) requiring mitral valve surgery
Tissues from the left atrial appendage [36] Microarray qPCR Upregulated: 466, 574-3p, 3613-3pDownregulated: 1, 26a-5p
12 patients with mitral stenosis (6 SR, 6 AF)
requiring mitral valve surgery
Mitral valve leaflets [38] RNA-seq Upregulated: 656, 379-3p, 664a-3p, 34c-3p 10 patients with myxomatousmitral valve vs. 10 controls
Mitral valve leaflets [39] whole genome miRNA qPCR Upregulated: 500, 3174Downregulated: 17, 203, 505, 646, 939, 1193, 1273e, 4298
10 myxomatous mitral valve
prolapse vs. fibroelastic deficiency
Abbreviations: AF, atrial fibrillation; AS, aortic stenosis; AVR, aortic valve replacement; BAV, bicuspid aortic valve; LV, left ventricle; TAV, tricuspid aortic valve; TAVI, transcatheter
aortic valve implantation; qPCR, quantitative real-time PCR.
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A recent study compared miRNA profiles in explanted mitral valves in MMVD and in fibroelastic
deficiency (FED), two common types of degenerative mitral valve disease [39]. miR-500, -3174, -17,
-1193, -646, -1273e, -4298, -203, -505, and -939 were differentially expressed in MMVP and FED. In silico
prediction of potential target genes revealed genes involved in extracellular matrix homeostasis
and genes encoding components of mitral valves (e.g., decorin, aggrecan, fibromodulin, α actin 2,
extracellular matrix protein 2, desmin, endothelial cell specific molecule 1, and platelet/endothelial
cell adhesion molecule 1). The expression of these gene mRNAs was inversely correlated with miRNA
expression in patient groups. This study provides first molecular evidence for the existence of distinct
mechanisms underlying MMVP and FED.
3.3. Circulating miRNA
Specific signatures of circulating miRNAs have been assigned to both acute and chronic CVD,
such as AF, CAD, myocardial infarction, heart failure, vascular disease, and cardiac death [40,41].
Cellular source of miRNAs can be diverse, including cardiomyocytes, endothelial cells, platelets and
fibroblasts, and release can occur in a disease-specific manner [42]. Whether the release of miRNAs
into the circulation is a passive or an active process remains unknown. Circulating miRNAs can be
delivered to recipient cells and modify their protein expression pattern [43].
The levels of miRNAs in serum and plasma are reproducible, consistent among individuals.
Circulating miRNAs are more stable than mRNAs and seem to be protected from endogenous
ribonuclease activity. Circulating miRNAs would indeed be stabilized by the formation of
Ago2-miRNA complex and/or protected from degradation by encapsulation in exosomes [44].
Seven studies compared the levels of candidate circulating miRNAs in AS cases vs. controls, with
the aim to identify AS specific miRNA (Table 2). Seven miRNAs were described to be differentially
expressed in the plasma of AS patients (miR-21 [31], miR-133 [30], miR-1 [32], miR-378 [45],
miR-210 and miR-22 [46], and miR-122 [33]). In these studies, high expression of miR-21 correlated
with mean transvalvular gradient and LV fibrosis, and miR-378 levels correlated with LV mass
index. miR-1 was associated with LV hypertrophy (LVH) and correlated with levels of soluble
heart-type fatty acid-binding protein-3 (FABP3), a lipid-binding protein and main target of peroxisome
proliferator-activated receptor γ (PPARγ). miR-378 was an indepedent predictor of LVH, while
miR-133a predicted LVH reversibility one year after surgery. Preoperative levels of circulating miR-133a
were significantly higher in the cohort of AS patients who normalized LV mass after pressure overload
release compared with those who maintained residual hypertrophy [30]. Increased miR-210 levels in
AS were comparable to increments of BNPs. Furthermore, miR-210 levels were associated with higher
mortality after 3.5 year follow-up. Another study compared patients with hypertrophic non-obstructive
or obstructive cardiomyopathy with AS patients and described specific upregulation of miR-29c in
AS [47]. Recently, Coffey et al. performed whole miRNome profiling in an effort to translate one
or more miRNAs into biomarkers for use in calcific AS [48]. Given the established link between
obstructive CAD and altered circulating miRNA profile [49], patients with or without CAD were
analyzed separately. Circulating whole miRNome profiles discriminate, albeit incompletely, between
participants with AS and those without. Two upregulated miRNAs, miR-451a and miR-22-3p, and
2 downregulated miRNAs, miR-24-3p and miR-382-5p, remained significantly different after adjusting
for age. In a validation cohort composed of patients with moderate or severe AS, in terms of mean aortic
valve maximum velocity, mean pressure gradient, and calculated aortic valve area, only miR-22-3p
and miR-382-5p had the expected results on qPCR, and these were observed only in patients with
CAD. In agreement with Villar et al. [31], miR-21-5p levels were higher in patients with AS without
CAD, but showed no difference between groups in those with CAD. miR-21-5p and miR-382-5p levels
showed a statistically significant correlation with maximum transvalvular velocity and mean gradient,
but not LV mass index.
In these studies, myocardial and plasma levels of miR-1 [32], miR-21 [31] and miR-133a [30]
correlated directly, supporting the myocardium as a relevant source of these miRNA. Notably, changes
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in valvular miRNA never correlated with modification of their plasma levels. We can therefore
anticipate that circulating miRNA will reflect mainly VHD-associated myocardial remodeling and
altered function. However, it seems that AS would still be characterized by distinct circulating miRNA
profiles. Indeed, Roncarati et al. [50] identified a profile of circulating miRNA that distinguishes
patients with hypertrophic cardiomyopathy (HCM) from healthy individuals. Three significantly
up-regulated miRNAs, miR-27a, -29a, and -199a-5, correlated with LV mass, whereas only miR-29a
correlated with fibrosis. Nevertheless, this profile was different from that of hypertrophy caused by
aortic stenosis, and may thus be disease specific. In severe AS, miR-29a levels were not increased
relative to the control group.
Table 2. Studies of circulating miRNAs as potential biomarkers for aortic stenosis.
Patients Methods Findings
75 AS patients requiring
AVR vs. 32 surgical controls [31] qPCR
High expression of miR-21 correlates with
mean transvalvular gradient and LV fibrosis
5 AS patients before
TAVI vs. healthy controls [32] qPCR
Decreased miR-1 correlates with increased
soluble FABP3 in AS patients upon LVH
112 patients with moderate to severe
AS vs. 40 healthy controls [45] qPCR
Lower levels of miR-1, miR-133a, and miR-378 in AS patients
miR-378 levels correlate with LV mass index
Independent predictor of LVH in AS
57 patients with moderate to severe
AS vs. 10 healthy controls [46] qPCR
Increased miR-210 levels in AS patients
comparable to increment in NT-proBNP levels
miR-210 levels associate with higher
mortality (3.5 year follow-up)
74 AS patients requiring AVR [30] qPCR miR-133a as a positive predictor of the hypertrophyreversibility after surgery
94 severe AS patients (with or without
CAD) vs. 101 controls [48]
Microarray
qPCR
miR-22-3p is upregulated in AS, while miR-382-5p was
downregulated, only in patients with CAD
miR-21-5p levels is higher only in AS without CAD
Only miR-21-5p and miR-382-5p levels correlate weakly
with measures of disease severity
23 patients with HNCM, 28 HOCM,
47 AS, 22 healthy controls [47] qPCR miR-29c is specifically upregulated in aortic stenosis
Abbreviations: AS, aortic stenosis; AVR, aortic valve replacement; CAD, coronary artery disease;
HNCM, hypertrophic non-obstructive cardiomyopathy; HOCM: hypertrophic obstructive cardiomyopathy;
LVH, left ventricular hypertrophy; TAVI, transcatheter aortic valve implantation; LV, left ventricle.
Circulating miRNAs have not been investigated in human mitral valve diseases. Two studies have
been performed in dogs with MMVD. Hulanicka et al. [51] analyzed the expression of nine candidate
miRNAs in the plasma of Dachshunds with MMVD and identified two significantly downregulated
miRNAs: cfa-miR-30b in dogs with moderate cardiac enlargement and cfa-miR-133b in dogs with
congestive heart failure. A second study investigated the expression of 277 miRNA in serum [52].
Dogs with MMVD and mild to moderate cardiac enlargement or with congestive heart failure had
four upregulated miRNAs, cfa-miR-103, cfa-miR-98, cfa-let-7b, and cfa-let-7c, while seven others were
downregulated (cfa-miR-302d, cfa-miR-380, cfa-miR-874, cfa-miR-582, cfa-miR-490, cfa-miR-329b, and
cfa-miR-487b), compared to normal dogs. Expression of six of these miRNAs also significantly differed
between dogs with congestive heart failure and those with mild to moderate cardiac enlargement
(cfa-miR-582, cfa-miR-487b, cfa-miR-103, cfa-miR-98, cfa-let-7b, and cfa-let-7c). The expression changes
were greater as disease severity increased.
4. Roles of miRNAs in VHD: Functional Studies
Few studies have undertaken functional analyses in cellular, mouse or zebrafish models in order to
gain mechanistic insight into the role of identified miRNA in aortic stenosis pathophysiology (Table 3,
Figure 1). Putative or proven target genes were highlighted.
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Table 3. miRNAs related to fibrocalcific valve remodelling or LV hypertrophy.
miRNA Model Target Genes Findings
Aortic valvular interstitial cells
miR-30b Human AVICs RUNX2, SMAD1, CASP3,SMAD3, BMP2, NOTCH1
miR-30b prevents osteogenesis and apoptosis through direct targeting of Runx2, Smad1, and caspase-3 [26]
Downregulates calcification-related gene pathways [24]
miR-26a Human AVICs ALPL, BMP2, SMAD1 miR-26a represses several calcification-related genes and increases mRNAlevel of genes that may have roles in inhibiting calcification (JAG2, SMAD7) [24]
miR-148a-3p Human AVICs IKBKB Exposition of AVICs to cyclic stretch represses miR-148a-3p, which activates the NF-κB-dependent inflammatory signalling pathway [27]
miR-141 Porcine AVICs BMP2 miR-141 inhibits osteoblastic transition of TGF-β stimulated VIC, possibly by targeting BMP-2 [25]
Fibroblasts
miR-122 Human fibroblasts TGFB1 Down-regulation of miR-122 contributes to fibrosis, possibly through TGF-β1 up-regulation [33]
miR-21 NIH3T3 fibroblast cell line - Stimulation with TGF-β induces p-SMAD2/3 interaction with DICER1, which promotes pre-miR-21 processing to mature miR-21 [53]
Left ventricle
miR-1 LV biopsies from AS patients FABP3
myocardial miR-1 expression was decreased whereas the circulating sFABP3 level was increased in AS patients compared with healthy subjects
miR-1 modulates the cellular and secreted levels of FABP3, which may
represent an indirect biomarker in the plasma, reflecting the cellular activity of miR-1 [32]
miR-21 LV biopsies from AS patients - LV myocardium from AS patients exhibits overexpression of DICER1 mRNA that is directly related to theexpression of TGF-β1, and its effectors SMAD2, and SMAD3, and to pre-miR-21 [53]
miR-21 LV biopsies from AS patients RECK, PDCD4 miR-21, its targets, and effectors of TGF-β signaling predict the variance of myocardial collagen [31]miR-21 plays a role in myocardial fibrosis
miR-133a LV biopsies from AS patients WHSC2 Combined myocardial miR-133a and clinical parameters predict LV mass normilisation 1 year after AVR [29,30]
Immune cells
miR-125b THP-1 monocytic cells CCL4 Chemokines are among the most upregulated genes in calcific AS valves, and adownregulation of miR-125b in infiltrating macrophages leads to increased CCL4 levels [28]
Mouse model of tranverse aortic constriction
miR-1 Myocardium of transgenic miceoverexpressing cardiac miR-1 FABP3
Ventricule pressure overload leads to cardiac hypertrophy, and results in a switch of the myocardium to a high metabolic energy demand,
which is paralleled by an increase of IGF-1 levels, and decreased miR-1
Inverse relationship between myocardial expression of miR-1 and circulating levels of FABP3 [32]
miR-21 Mouse myocardium - TGF-β induces miR-21 up-regulation in myocardium under pressure overload, which contributes to maladaptive remodelling and fibrosis [31]
miR-21 Mouse myocardium - Pressure overload upregulates myocardial DICERDICER transcript levels correlate directly with TGF-β1, SMAD2, and SMAD3 [53]
Zebrafish development
miR-21 Zebrafish heart valve spry2, pdcd4a, ptenb miR-21 is a central component of a flow-controlled mechanotransduction systemduring heart valve formation, acting as a positive regulator of cell proliferation [54]
Abbreviations: AS, aortic stenosis; AVIC, aortic valve interstitial cells; AVR, aortic valve replacement; BMP-2, Bone morphogenetic protein-2; CCL4, Chemokine (C–C motif) ligand 4;
DICER1, Double-Stranded RNA-Specific Endoribonuclease; LV, left ventricle; SMAD2/3, SMAD Family Member 2/3; p-SMAD2/3, phosphorylated-SMAD2/3; TGF-β, transforming
growth factor-β.
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In a mouse model of pressure overload-induced LV remodelling by transverse aortic
constriction, elevated levels of miR-21 were observed, attributing a role for this miRNA in
myofibroblast differentiation and maladaptive LV fibrosis by targeting effectors of TGF-β1 signaling,
i.e., programmed cell death 4 (PDCD4) and Reversion Inducing Cysteine Rich Protein With
Kazal Motifs (RECK), a negative regulator of MMP-9 [31]. Interestingly, the recent study by
Garcia et al. [53] indicated that TGF-β1-induced phosphorylation of SMAD2/3 caused the interaction
of p-SMAD2/3 with the cytoplasmic endonuclease RNase III DICER1, which promoted pre-miR-21
processing to mature miR-21. In a zebrafish model, miR-21 appeared as a central component of a
flow-controlled mechanotransduction system during valvulogenesis acting as a positive regulator of
cell proliferation [54], a process that could also be implicated in pathological remodelling of the valves.
Thus, there is strong evidence that pressure overload leads to increased myocardial miR-21 in both
animal and human models, which controls LV remodelling and fibrosis by acting on myocardial cell
differentiation and/or proliferation.
In a general manner, miRNAs have been involved in fibrosis, mainly targeting ECM structural
proteins or enzymes involved in ECM remodelling, in pro-fibrotic TGF-β signaling pathways, and
connective tissue growth factor (CTGF). They also affect epithelial-to-mesenchymal transition, induce
myofibroblast proliferation, and their resistance to apoptosis [55]. More particularly, miR-21 has been
involved in fibrosis in the heart, but also in lung and kidney. In different cell types isolated from
failing hearts, miR-21 was predominantly upregulated in cardiac fibroblasts, and mediated protection
from apoptosis, possibly through activation of extracellular signal-regulated kinase/mitogen activated
protein kinase (ERK/MAPK) signaling [56]. Sprouty1, a negative regulator of ERK/MAPK, was
identified as the direct target of miR-21. However, in the mice, miR-21 seems not to be essential
for ERK/MAPK activation in stress-dependent cardiac remodeling [57]. Further investigations
are warranted to determine whether these mechanisms contribute to VHD-associated valvular and
LV fibrosis.
Data from AS patients LV biopsies suggest that the miR-133a-Wolf-Hirschhorn Syndrome
Candidate 2 (WHSC2) axis could also play a role in the regulation of cardiac hypertrophy [30]. It has
been described that miR-133 plays a key role in the control of the trophic state of the heart under normal
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conditions and that, when miR-133 is down-regulated, such as in the pressure overload condition,
the transcriptional derepression of genes encoding proteins that regulate cardiac structure likely
contributes to the adverse remodeling response [58,59]. The WHSC2 gene, also known as NELF-A,
encodes a component of the Negative Elongation Factor complex involved in the regulation of RNA
polymerase II transcription elongation. However, the mechanistic link of the miR-133a-WHSC2 axis
with AS pathophysiology remains to be determined.
Pressure overload has also been associated with decreased expression of myocardial miR-1 in a
mouse model of transverse aortic constriction and in AS patients [32]. In this study, decreased miR-1
expression correlated directly with increased levels of the cardiac-type fatty acid binding protein 3
(FABP3). Of interest, FABP3 is involved in the control of lipid metabolism through its role in the
uptake, intracellular metabolism and transport of long-chain fatty acids. Thus, downregulation
of miR-1 in AS may reflect the switch of the myocardium to a high metabolic energy demand,
accompanying the cardiac hypertrophy response through FABP3 upregulation and subsequent
myocardial metabolic remodeling.
Of note, miR-133 originates from the same bicistronic transcript as miR-1, and it has been reported
that both miR-133 and miR-1 play important roles in generating cardiomyocytes from embryonic stem
cells and in reprogramming human fibroblasts to cardiac-like myocytes [60,61]. There are only few
miRNA families regulating biological processes in the heart, and miR-1 is probably one of the most
abundant [62]. miR-1 is upregulated in individuals with coronary artery disease and its overexpression
worsens arrhythmogenesis. However, the majority of the studies agree on the fact that miR-1 plays
a protective role against cardiac hypertrophy or heart failure by targeting several genes related to
hypertrophy, e.g., calmodulin, Mef2a, insulin-like growth factor-1, insulin-like growth factor-1R, and
sodium–calcium exchanger. Whether these mechanisms contribute to AS-associated LV hypertrophy
remains to be determined.
In the valves, miRNAs may play an important role in osteoblast transition of VICs [63].
Four studies used human aortic VICs and showed functional implication of miR-30b in the prevention
of abnormal osteogenesis and apoptosis by direct targeting of Runt-related transcription factor 2
(RUNX-2), SMAD-1, and caspase-3 [24,26]. Likewise, miR-26a represses several calcification-related
genes [24], and therefore, downregulation of these miRNAs would alleviate protective mechanisms,
leading to valve calcification. Exposure of aortic VICs to cyclic stretch downregulates miR-148-3p,
resulting in the activation of inflammation through NF-κB signaling pathway [27]. Thus, abnormal
haemodynamics encountered in AS would drive an inflammatory response yielding immune cell
recruitment to the valve and subsequent calcification. Using TGF-β-stimulated porcine AVICs, miR-141
was identified to inhibit osteoblastic transition, possibly by repressing BMP-2 [25]. Downregulation
of miR-125b in infiltrating macrophages would result in increased levels of the CCL4 chemokine,
promoting immune cell recruitment [28]. In fibroblasts, downregulation of miR-122 would contribute
to fibrosis, possibly through TGF-β1 upregulation [33].
Among other miRNAs that are downregulated in aortic stenosis, it has been described that
miR-210 contributes to osteoblast differentiation by repressing the activity of the TGF-β type I
receptor as part of the osteoblast lineage commitment program [64]. Likewise, miR-29 regulates
osteoblast differentiation by inhibiting osteonectin expression through the canonical Wnt pathway.
However, functional evidence is lacking to determine whether these regulatory mechanisms would
apply to valve calcification processes.
Circulating miRNAs could be involved in paracrine communication between blood cells, VEC and
VIC, contributing to tissue homeostasis. Changes in haemodynamics may have an effect on miRNA
expression that could be responsible for disease progression [65].
In this context, it has been reported that platelet-derived microparticles mediate transfer of
their cargo between platelets and other cells [66,67], and disease-associated dysregulation of miRNA
content in platelets might therefore affect other cells, serving as paracrine signaling molecules.
Several studies on human platelets indicate that miRNA content varies in different disease states [68].
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For instance, levels of platelet miRNAs in the circulation have been associated with atrial fibrillation
and peripheral vascular disease [69]. Microparticles produced upon platelet activation can be cargos
of Ago2-microRNA complexes that are delivered to endothelial cells [70]. Since platelet activation
has been associated with calcific AS, platelet-derived miRNAs might thus have important roles
as biomarkers of disease diagnosis, prognosis, or treatment. Besides, recent evidence attributes
mechanistic roles for platelet-derived miRNAs in haemostasis, thrombosis, and unstable coronary
syndromes. Further investigations are required to determine if platelet-derived miRNAs could
contribute to VHD progression and serve as biomarkers.
Furthermore, recent evidence indicate that extracellular vesicles derived from smooth muscle
cells, VICs and macrophages could mediate calcification in diseased heart valves [71]. These calcifying
vesicles are indeed loaded with miRNAs that target genes involved in osteogenic differentiation,
among which miR-30 and miR-125b could be particularly relevant to VHD. However, the regulation of
EV release, and the mechanisms of interaction between EVs and the extracellular matrix leading to the
formation of microcalcifications remain unclear.
Thus, despite the identification of few miRNAs with potential diagnostic or pronostic significance
in VHD, most of the studies are still preliminary, because of limited numbers of miRNAs measured
or small size of patient cohorts. As a consequence, only modest correlation with disease severity
was reported, and identified miRNAs are unlikely to provide sufficient discrimination between
heterogeneous groups of patients.
5. miRNA Therapeutics
Optimal therapeutic strategy would target early stages of disease development before valve
calcification becomes irreversible. Studies indicate that miRNA could be important regulators of both
fibrosis and calcific nodule formation. Beyond their potential use as biomarkers of disease onset and
progression, miRNA-based therapeutics could also be envisioned.
A single miRNA can target several mRNAs and a group of miRNAs can target genes from the
same pathway, suggesting that miRNA targeting could simultaneously affect a number of relevant
dysregulated gene networks.
A new class of drugs that specifically targets miRNA is presently in development. Three main
approaches have been exploited: expression vectors (miRNA sponges), small-molecule inhibitors and
antisense oligonucleotides (ASOs) [72].
It has been proposed that anti-miR-mediated silencing could be a powerful strategy for the
treatment of human disease [72]. However, a number of concerns remain before such therapies can
be translated to clinical applications. The first difficulty is to find out strategies that would deliver
miRNA to target tissues. The major obstacle is the off-target effects. Specificity can be improved by
using several miRNAs that target a single mRNA. Increase of desired effect could also be achieved by
selecting a miRNA that targets multiple genes within a same pathway.
In aortic stenosis, we can anticipate that anti-miR-21 approaches could be useful to limit cardiac
valve or LV fibrosis. miR-133-based therapies may be directed to manipulate the trophic state of the
heart. miR-1 or miR-133a mimics would synergize with conventional medical and surgical measures
to achieve reverse remodeling of the overloaded LV. Local delivery of mimics of miR-26a, miR-30b,
miR-141, or miR-148a-3p could be envisionned to counteract valve calcification.
6. Conclusions
Current knowledge allows us to assert that miRNAs might represent important regulators of
VHD development. Most studies focused on aortic stenosis, while the role of miRNA in mitral
valve diseases remains largely unknown. Notwithstanding, available data suggest that distinct
miRNA are dysregulated in aortic and mitral valve diseases, supporting different underlying
pathophysiological mechanisms.
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In AS, miRNAs could contribute to changes in VIC phenotype that occur under disturbed flow,
and they could regulate key processes underlying VHD, i.e., fibrosis, calcification, LV remodelling,
thrombosis and inflammation.
These miRNAs certainly warrant further investigation. Future studies using larger patient cohorts
as well as animal models will have to be designed to address two important challenges. The first
challenge would be to identify miRNA biomarkers consistently dysregulated in specific VHD and at
different stages of disease progression, miRNAs that could be markers of patient response to therapy,
or that could serve to monitor post-surgery events. We believe that miRNA could be included in a
multi-biomarker approach combined with high resolution imaging modalities to assess small changes
in the leaflets. Such an approach could provide the potential to obtain a global view on molecular and
cellular processes that have an impact on disease onset, and could be the basis for a more personalised
and predictive medicine. The second challenge would focus on the assessment of miRNA function in
order to evaluate the possibility to target miRNA and related proteins as new therapeutic avenues.
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AVIC Aortic valve interstitial cells
AVR Aortic valve replacement
BAV Bicuspid aortic valve
BMP-2 Bone morphogenetic protein-2
BNP B-type natriuretic peptide
CAD Coronary artery disease
CCL4 Chemokine (C–C motif) ligand 4
HNCM Hypertrophic non-obstructive cardiomyopathy
HOCM Hypertrophic obstructive cardiomyopathy
LV Left ventricle
LVH Left ventricular hypertrophy
MMVD Myxomatous mitral valve degeneration
SMAD2/3 Mothers against decapentaplegic homolog (SMAD) family member 2/3
p-SMAD2/3 Phosphorylated-SMAD2/3
TAC Transverse aortic constriction
TAV Tricuspid aortic valve
TAVI Transcatheter aortic valve implantation
TGF-β Transforming growth factor-β
VEC Valve endothelial cells
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